» Articles » PMID: 25997673

Redefining Risk Categories for Pneumococcal Disease in Adults: Critical Analysis of the Evidence

Overview
Publisher Elsevier
Date 2015 May 23
PMID 25997673
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To analyze the available published data (2005-2014) describing the prevalence of multimorbidity in adult patients with pneumococcal disease, with a focus on the comorbidities considered by the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention to increase the risk of pneumococcal disease in adults (immunocompetent persons with chronic medical conditions (at risk) and immunocompromised or immunosuppressed persons (high risk)). An analysis of case-control and population-based surveillance studies that have evaluated risk factors for community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) was also performed in order to estimate the importance of risk stacking.

Methods: Studies that established the enrolment procedure for patients and reported the incidence of multimorbidity and risk factors for CAP and/or IPD were included. In order to obtain a risk stacking value based on the at-risk comorbidity odds ratios (OR), the multiplicative method described by Campbell was used.

Results: Thirty-eight articles were selected, 19 for multimorbidity and 19 for risk factors for CAP/IPD. With regard to multimorbidity, the prevalence among adults aged ≥65 years ranged from 23% to 98.7% for two or more comorbidities and from 18% to 89.7% for three or more comorbidities. Diabetes (DBT), chronic heart disease (CHD), and chronic obstructive pulmonary disease (COPD) were the three most frequent comorbidities described (7.6-28.5%, 6.9-25.8%, and 3.8-15.4%, respectively). With regard to risk factors, based on the multiplicative method, the hypothetical scenario of concurrence of the three most frequent at-risk conditions (DBT+CHD+COPD) showed an OR of ≥7.5. In this group of patients, the addition of smoking, another common at-risk factor for CAP (stacking four concurrent conditions) increased the OR from 8.5 to >40. These ORs were generally similar to rates described by other authors in persons with a high risk.

Conclusions: The ORs for CAP and IPD of patients with two or more comorbidities, with or without smoking, were found to be similar to the ORs for CAP and IPD described in the literature for patients currently classified as high risk. The potential impact of multiple, stacking comorbidities is underestimated and there is a need for the risk categories for pneumococcal disease to be redefined.

Citing Articles

Pneumococcal disease burden in high-risk older adults: Exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review.

Cheong D, Song J Hum Vaccin Immunother. 2024; 20(1):2429235.

PMID: 39631047 PMC: 11622649. DOI: 10.1080/21645515.2024.2429235.


Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study.

Ochoa-Gondar O, Torras-Vives V, de Diego-Cabanes C, Satue-Gracia E, Vila-Rovira A, Forcadell-Perisa M BMC Pulm Med. 2023; 23(1):200.

PMID: 37291502 PMC: 10251659. DOI: 10.1186/s12890-023-02497-2.


Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A....

Hammitt L, Quinn D, Janczewska E, Pasquel F, Tytus R, Reddy K Hum Vaccin Immunother. 2023; 19(1):2177066.

PMID: 36864601 PMC: 10026908. DOI: 10.1080/21645515.2023.2177066.


Characterization of the innate immune response to Streptococcus pneumoniae infection in zebrafish.

Saralahti A, Harjula S, Rantapero T, Uusi-Makela M, Kaasinen M, Junno M PLoS Genet. 2023; 19(1):e1010586.

PMID: 36622851 PMC: 9858863. DOI: 10.1371/journal.pgen.1010586.


Serotype distribution of and pneumococcal vaccine coverage in adults in Turkey between 2015 and 2018.

Hascelik G, Soyletir G, Gulay Z, Sancak B, Yaman A, Gurler N Ann Med. 2022; 55(1):266-275.

PMID: 36579976 PMC: 9809394. DOI: 10.1080/07853890.2022.2160877.